Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free MENS Stock Alerts

Jyong Biotech (MENS) Competitors

Jyong Biotech logo
$2.08 +0.06 (+2.97%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$2.08 0.00 (0.00%)
As of 05/14/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MENS vs. TRDA, PRME, CRMD, DNA, and PRTA

Should you buy Jyong Biotech stock or one of its competitors? MarketBeat compares Jyong Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jyong Biotech include Entrada Therapeutics (TRDA), Prime Medicine (PRME), CorMedix (CRMD), Ginkgo Bioworks (DNA), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

How does Jyong Biotech compare to Entrada Therapeutics?

Jyong Biotech (NASDAQ:MENS) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Entrada Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 167.20%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entrada Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

Jyong Biotech has higher earnings, but lower revenue than Entrada Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
Entrada Therapeutics$25.42M10.43-$143.75M-$3.99N/A

In the previous week, Entrada Therapeutics had 16 more articles in the media than Jyong Biotech. MarketBeat recorded 17 mentions for Entrada Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Entrada Therapeutics' score of 0.47 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Very Positive
Entrada Therapeutics Neutral

Jyong Biotech has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Jyong Biotech's return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Entrada Therapeutics -2,895.05%-51.22%-42.20%

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Entrada Therapeutics beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Jyong Biotech (NASDAQ:MENS) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Jyong Biotech has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Jyong Biotech's return on equity of 0.00% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-4,917.55% -188.82% -60.97%
Jyong Biotech N/A N/A N/A

70.4% of Prime Medicine shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jyong Biotech has lower revenue, but higher earnings than Prime Medicine.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M122.10-$201.14M-$1.23N/A
Jyong BiotechN/AN/AN/AN/AN/A

Prime Medicine presently has a consensus target price of $7.38, suggesting a potential upside of 135.62%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Prime Medicine is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Prime Medicine had 9 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Prime Medicine and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Prime Medicine's score of 0.35 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Prime Medicine Neutral
Jyong Biotech Very Positive

Summary

Prime Medicine beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

CorMedix has a net margin of 52.31% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 52.30% beat Jyong Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
CorMedix52.31% 52.30% 29.46%
Jyong Biotech N/A N/A N/A

34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CorMedix has higher revenue and earnings than Jyong Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorMedix$311.71M2.00$163.05M$2.003.97
Jyong BiotechN/AN/AN/AN/AN/A

CorMedix currently has a consensus target price of $15.00, suggesting a potential upside of 89.16%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorMedix
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, CorMedix had 11 more articles in the media than Jyong Biotech. MarketBeat recorded 12 mentions for CorMedix and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat CorMedix's score of 0.63 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
CorMedix Positive
Jyong Biotech Very Positive

Summary

CorMedix beats Jyong Biotech on 10 of the 11 factors compared between the two stocks.

How does Jyong Biotech compare to Ginkgo Bioworks?

Jyong Biotech (NASDAQ:MENS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Ginkgo Bioworks had 9 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Ginkgo Bioworks' score of -0.19 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Very Positive
Ginkgo Bioworks Neutral

Jyong Biotech has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Jyong Biotech's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Ginkgo Bioworks -215.41%-56.08%-26.06%

Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential upside of 8.77%. Given Ginkgo Bioworks' stronger consensus rating and higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jyong Biotech has higher earnings, but lower revenue than Ginkgo Bioworks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
Ginkgo Bioworks$151.40M3.20-$312.76M-$5.36N/A

Summary

Ginkgo Bioworks beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Jyong Biotech compare to Prothena?

Jyong Biotech (NASDAQ:MENS) and Prothena (NASDAQ:PRTA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Prothena had 16 more articles in the media than Jyong Biotech. MarketBeat recorded 17 mentions for Prothena and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Prothena's score of -0.08 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Very Positive
Prothena Neutral

Jyong Biotech has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Jyong Biotech's return on equity of 0.00% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Prothena -260.92%-43.44%-36.87%

Prothena has a consensus target price of $21.78, indicating a potential upside of 120.87%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jyong Biotech has higher earnings, but lower revenue than Prothena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
Prothena$9.68M53.32-$244.09M-$2.82N/A

Summary

Prothena beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MENS vs. The Competition

Export
MetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$153.58M$935.59M$4.28B$12.38B
Dividend YieldN/A4.84%6.42%5.35%
P/E RatioN/A1.4822.8025.63
Price / SalesN/A115.81158.7876.62
Price / CashN/A20.0753.4656.33
Price / BookN/A8.1136.806.97
Net IncomeN/A-$3.91M$113.55M$333.62M
7 Day Performance1.46%9.43%2.85%1.09%
1 Month Performance-20.91%76.62%5.01%3.08%
1 Year PerformanceN/A140.55%15.70%35.68%

Jyong Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MENS
Jyong Biotech
N/A$2.08
+3.0%		N/AN/A$153.58MN/AN/A31
TRDA
Entrada Therapeutics
3.6658 of 5 stars		$15.66
-0.8%		$19.00
+21.4%		-14.3%$608.35M$25.42MN/A110
PRME
Prime Medicine
2.2755 of 5 stars		$3.38
-2.7%		$7.38
+118.5%		N/A$607.79M$4.63MN/AN/A
CRMD
CorMedix
3.0061 of 5 stars		$7.71
-2.5%		$15.00
+94.7%		-31.8%$604.38M$311.71M3.8530
DNA
Ginkgo Bioworks
1.272 of 5 stars		$9.74
-1.7%		$8.50
-12.7%		+0.3%$603.10M$170.15MN/A640

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel